Linked Life Data

17884370

Source:http://linkedlifedata.com/resource/pubmed/id/17884370

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2007-9-21
pubmed:abstractText
Adjunctive glycoprotein IIb/IIIa inhibition decreases ischemic events after percutaneous coronary intervention (PCI) but is associated with increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, a thienopyridine, and a glycoprotein IIb/IIIa inhibitor without unfractionated heparin (UFH) would result in fewer bleeding complications and maintain efficacy in elective PCI. A total of 159 patients undergoing elective PCI were randomized to intraprocedural eptifibatide alone or eptifibatide plus UFH. Patients received aspirin 325 mg and clopidogrel 300 mg before the procedure. The primary end point was the Landefeld bleeding index. Secondary end points included the composite clinical outcome of in-hospital death, myocardial infarction, urgent target vessel revascularization, and Thrombolysis In Myocardial Infarction major bleeding, and a composite bleeding outcome of major, minor, and nuisance bleeding. The Landefeld bleeding index was significantly lower in the eptifibatide-only group compared with the eptifibatide-plus-UFH group (3.0 vs 3.9, p = 0.03). There was no significant difference in the composite clinical end point between groups (eptifibatide only 17% vs eptifibatide plus UFH 15%, p = 0.7). There was a trend toward a decrease in the composite bleeding end point in the eptifibatide-only compared with the eptifibatide-plus-UFH group (43% vs 56%, p = 0.10). In conclusion, during elective PCI, a strategy of aggressive antiplatelet therapy using aspirin, clopidogrel, and eptifibatide without anticoagulant therapy appears to decrease bleeding complications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1099-102
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17884370-Adolescent, pubmed-meshheading:17884370-Adult, pubmed-meshheading:17884370-Aged, pubmed-meshheading:17884370-Aged, 80 and over, pubmed-meshheading:17884370-Angioplasty, Balloon, Coronary, pubmed-meshheading:17884370-Anticoagulants, pubmed-meshheading:17884370-Aspirin, pubmed-meshheading:17884370-Coronary Artery Disease, pubmed-meshheading:17884370-Drug Therapy, Combination, pubmed-meshheading:17884370-Female, pubmed-meshheading:17884370-Heparin, pubmed-meshheading:17884370-Humans, pubmed-meshheading:17884370-Male, pubmed-meshheading:17884370-Middle Aged, pubmed-meshheading:17884370-Peptides, pubmed-meshheading:17884370-Pilot Projects, pubmed-meshheading:17884370-Platelet Aggregation Inhibitors, pubmed-meshheading:17884370-Prospective Studies, pubmed-meshheading:17884370-Pyridines, pubmed-meshheading:17884370-Ticlopidine, pubmed-meshheading:17884370-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).
pubmed:affiliation
Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't